Sugi Predict

Sugi Predict / Compounds / SCHEMBL826933

SCHEMBL826933

SCHEMBL826933

NC(CCCC1OCCO1)C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GSR P00390 2/20 0.48
▸ ARG2 P78540 4/20 0.44
▸ ARG1 P05089 3/20 0.44
▸ NOS2 P35228 5/20 0.43
▸ CYP1A2 P05177 3/20 0.43
▸ CYP2C19 P33261 2/20 0.43
▸ TSHR P16473 2/20 0.43
▸ GLA P06280 1/20 0.43
▸ NFKB1 P19838 1/20 0.43
▸ APEX1 P27695 1/20 0.43
▸ GRM8 O00222 1/20 0.42
▸ GRM6 O15303 1/20 0.42
▸ GRIN2D O15399 1/20 0.42
▸ GRIN3B O60391 1/20 0.42
▸ GRIK1 P39086 1/20 0.42
▸ GRM5 P41594 1/20 0.42
▸ GRIA1 P42261 1/20 0.42
▸ GRIA2 P42262 1/20 0.42
▸ GRIA3 P42263 1/20 0.42
▸ SLC1A3 P43003 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL231631 1.00 GSR (0.48) GSRARG2ARG1NOS2CYP1A2
SCHEMBL5668298 1.00 GSR (0.48) GSRARG2ARG1NOS2CYP1A2
SCHEMBL10238195 0.94 GSR (0.52) GSRARG2ARG1NOS2CYP1A2
SCHEMBL21083190 0.93 GSR (0.50) GSRARG2ARG1NOS2CYP1A2
SCHEMBL826645 0.93 GSR (0.50) GSRARG2ARG1NOS2CYP1A2
SCHEMBL19417862 0.93 GSR (0.46) GSRARG2ARG1NOS2CYP1A2
SCHEMBL15634459 0.88 GSR (0.45) GSRARG2ARG1CYP1A2GRM8
SCHEMBL826512 0.88 GSR (0.45) GSRARG2ARG1CYP1A2GRM8
SCHEMBL4981473 0.85 NOS2 (0.32) GSRNOS2CYP1A2CYP2C19TSHR
SCHEMBL14189195 0.85 NOS2 (0.32) GSRNOS2CYP1A2CYP2C19TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 286 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12037405-B2 Anti-CD70 antibody drug conjugates AMBRX, INC. 2024-07-16 — — US disclosed
US-12037405-B2 Anti-CD70 antibody drug conjugates AMBRX, INC. 2024-07-16 — — US disclosed
EP-4389145-A2 INTERLEUKIN-2 POLYPEPTIDE CONJUGATES AND THEIR USES Ambrx, Inc. (US) 2024-06-26 — — EP disclosed
EP-3572091-B1 MODIFIED RELAXIN POLYPEPTIDES AND THEIR USES AMBRX INC (US) 2023-12-13 — — EP disclosed
US-20230348547-A1 MODIFIED BOVINE G-CSF POLYPEPTIDES AND THEIR USES AMBRX INC (US) 2023-11-02 — — US disclosed
US-11786578-B2 Modified relaxin polypeptides and their uses AMBRX, INC. (US) 2023-10-17 — — US disclosed
US-11786578-B2 Modified relaxin polypeptides and their uses AMBRX, INC. (US) 2023-10-17 — — US disclosed
US-20230302150-A1 ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF AMBRX, INC. (US) 2023-09-28 — — US disclosed
US-20230302150-A1 ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF AMBRX, INC. (US) 2023-09-28 — — US disclosed
US-20230295320-A1 Anti-CD70 Antibody Drug Conjugates AMBRX, INC. (US) 2023-09-21 — — US disclosed
US-6468781-B1 USING RECOMBINANT METHYLOTROPHIC YEAST HOST CELL CAPABLE OF PRODUCING BOTH PHENYLALANINE DEHYDROGENASE AND FORMATE DEHYDROGENASE BRISTOL-MYERS SQUIBB COMPANY 2002-10-22 — — US disclosed
US-20020049342-A1 Substituted alkylketo compounds and process HANSON RONALD L (US) 2002-04-25 — — US disclosed
US-6291701-B1 USED AS CHEMICAL INTERMEIDATE DSM N.V. (NL) 2001-09-18 — — US disclosed
EP-1097236-A1 STEREOSELECTIVE REDUCTIVE AMINATION OF KETONES BRISTOL-MYERS SQUIBB COMPANY (US) 2001-05-09 — — EP disclosed
US-6222052-B1 FOR USE IN THE PREPARATION OF D-PIPECOLIC ACID DERIVATIVES DSM N.V. (NL) 2001-04-24 — — US disclosed
US-6140088-A Stereoselective reductive amination of ketones BRISTOL-MYERS SQUIBB COMPANY (US) 2000-10-31 — — US disclosed
US-6133002-A ACETALIZATION OF DIALDEHYDE WITH ALCOHOL, DIOL, OR ORTHOFORMIC ESTER; AMINATION, CYANATION, OXIDATION; ENANTIOSELECTIVE HYDROLYSIS DSM N.V. (NL) 2000-10-17 — — US disclosed
WO-2000004179-A1 STEREOSELECTIVE REDUCTIVE AMINATION OF KETONES BRISTOL-MYERS SQUIBB COMPANY (US) 2000-01-27 — — WO disclosed
CN-1218797-A Process for preparing optical 2-amino-omega-oxo alkane acid derivative DSM CO LTD (NL) 1999-06-09 — — CN disclosed
EP-0905257-A1 Process for preparing optically active 2-amino-Omega-oxoalkanoic acid derivatives DSM N.V. (NL) 1999-03-31 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12037405-B2 Anti-CD70 antibody drug conjugates CD74, CD63, CD47 GSR 4873/4885ARG2 1614/4885ARG1 942/4885
US-20020049342-A1 Substituted alkylketo compounds and process DAO, KMO, BCAT1 GSR 4646/4885ARG2 2506/4885ARG1 967/4885
US-20230302150-A1 ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF TLR3, TLR1, TLR9 GSR 4178/4885ARG2 2985/4885ARG1 3033/4885
US-20230348547-A1 MODIFIED BOVINE G-CSF POLYPEPTIDES AND THEIR USES CSF3R, GMFG, HDGF GSR 2625/4885ARG2 428/4885ARG1 75/4885
US-20230295320-A1 Anti-CD70 Antibody Drug Conjugates CD63, CD74, CD99 GSR 4870/4885ARG2 2175/4885ARG1 1167/4885
US-11786578-B2 Modified relaxin polypeptides and their uses RXFP1, RXFP2, RXFP3 GSR 3276/4885ARG2 57/4885ARG1 39/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.